SENATE BILL 357
J1, J5 (5lr2092)
ENROLLED BILL
— Finance/Health and Government Operations —
Introduced by Senators Gile and Feldman, Feldman, and Hester
Read and Examined by Proofreaders:
_______________________________________________
Proofreader.
_______________________________________________
Proofreader.
Sealed with the Great Seal and presented to the Governor, for his approval this
_______ day of _______________ at ________________________ o’clock, ________M.
______________________________________________
President.
CHAPTER ______
1 AN ACT concerning
2 Prescription Drug Affordability Board – Authority for Upper Payment Limits
3 and Stakeholder Council Membership
4 (Lowering Prescription Drug Costs for All Marylanders Now Act)
5 FOR the purpose of altering the membership of the Prescription Drug Affordability
6 Stakeholder Council; requiring the Prescription Drug Affordability Board, under
7 certain circumstances, to establish a process for setting upper payment limits for all
8 purchases and payor reimbursements of prescription drug products in the State that
9 the Board determines have led or will lead to affordability challenges; authorizing
10 the Board to reconsider an upper payment limit for a drug that becomes a current
11 shortage; altering requirements related to the setting of upper payment limits by the
12 Board; requiring the Board to confer with the Maryland Medical Assistance Program
13 before establishing an upper payment limit that applies to the Program; prohibiting
14 the Board from taking certain actions related to upper payment limits; and generally
15 relating to the Prescription Drug Affordability Board.
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
Strike out indicates matter stricken from the bill by amendment or deleted from the law by
amendment.
Italics indicate opposite chamber/conference co mm i tte e a m en dm en ts*. sb0357*

2 SENATE BILL 357
1 BY repealing and reenacting, with amendments,
2 Article – Health – General
3 Section 21–2C–01, 21–2C–04, 21–2C–13, and 21–2C–14
4 Annotated Code of Maryland
5 (2023 Replacement Volume and 2024 Supplement)
6 BY repealing and reenacting, without amendments,
7 Article – Health – General
8 Section 21–2C–09(c) and 21–2C–11(a)
9 Annotated Code of Maryland
10 (2023 Replacement Volume and 2024 Supplement)
11 BY adding to
12 Article – Health – General
13 Section 21–2C–09(d) and (e) and 21–2C–16
14 Annotated Code of Maryland
15 (2023 Replacement Volume and 2024 Supplement)
16 BY repealing
17 Article – Health – General
18 Section 21–2C–11(d) and 21–2C–16
19 Annotated Code of Maryland
20 (2023 Replacement Volume and 2024 Supplement)
21 BY adding to
22 Article – Health – General
23 Section 21–2C–16
24 Annotated Code of Maryland
25 (2023 Replacement Volume and 2024 Supplement)
26 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
27 That the Laws of Maryland read as follows:
28 Article – Health – General
29 21–2C–01.
30 (a) In this subtitle the following words have the meanings indicated.
31 (b) “Biologic” means a drug that is produced or distributed in accordance with a
32 biologics license application approved under 42 C.F.R. § 447.502.
33 (c) “Biosimilar” means a drug that is produced or distributed in accordance with
34 a biologics license application approved under 42 U.S.C. § 262(k)(3).
35 (d) “Board” means the Prescription Drug Affordability Board.

SENATE BILL 357 3
1 (e) (1) “Brand name drug” means a drug that is produced or distributed in
2 accordance with an original new drug application approved under 21 U.S.C. § 355(c).
3 (2) “Brand name drug” does not include an authorized generic as defined
4 by 42 C.F.R. § 447.502.
5 (F) “CURRENT SHORTAGE” MEANS A DRUG:
6 (1) LISTED AS CURRENT ON THE FEDERAL FOOD AND DRUG
7 ADMINISTRATION’S DRUG SHORTAGE DATABASE; OR
8 (2) OTHERWISE DETERMINED BY THE BOARD TO BE IN SHORT
9 SUPPLY IN THE STATE.
10 [(f)] (G) “Generic drug” means:
11 (1) A retail drug that is marketed or distributed in accordance with an
12 abbreviated new drug application, approved under 21 U.S.C. § 355(j);
13 (2) An authorized generic as defined by 42 C.F.R. § 447.502; or
14 (3) A drug that entered the market before 1962 that was not originally
15 marketed under a new drug application.
16 [(g)] (H) “Manufacturer” means an entity that:
17 (1) (i) Engages in the manufacture of a prescription drug product; or
18 (ii) Enters into a lease with another manufacturer to market and
19 distribute a prescription drug product under the entity’s own name; and
20 (2) Sets or changes the wholesale acquisition cost of the prescription drug
21 product it manufactures or markets.
22 [(h)] (I) “Prescription drug product” means a brand name drug, a generic drug,
23 a biologic, or a biosimilar.
24 [(i)] (J) “Stakeholder Council” means the Prescription Drug Affordability
25 Stakeholder Council.
26 21–2C–04.
27 (a) There is a Prescription Drug Affordability Stakeholder Council.

4 SENATE BILL 357
1 (b) The purpose of the Stakeholder Council is to provide stakeholder input to
2 assist the Board in making decisions as required under this subtitle.
3 (c) (1) The Stakeholder Council consists of [26] members appointed in
4 accordance with this subsection.
5 (2) The Speaker of the House of Delegates shall appoint:
6 (i) One representative of generic drug corporations;
7 (ii) One representative of nonprofit insurance carriers;
8 (iii) One representative of a statewide health care advocacy coalition;
9 (iv) One representative of a statewide advocacy organization for
10 seniors;
11 (v) One representative of a statewide organization for diverse
12 communities;
13 (vi) One representative of a labor union;
14 (vii) ONE REPRESENTATIVE OF THE RARE DISEASE COMMUNITY;
15 (VIII) One health services researcher specializing in prescription
16 drugs; and
17 [(viii)] (IX) One public member at the discretion of the Speaker of the
18 House of Delegates.
19 (3) The President of the Senate shall appoint:
20 (i) One representative of brand name drug corporations;
21 (ii) One representative of physicians;
22 (iii) One representative of nurses;
23 (iv) One representative of hospitals;
24 (v) One representative of dentists;
25 (vi) ONE REPRESENTATIVE OF ONCOLOGISTS;
26 (VII) One representative of managed care organizations;

SENATE BILL 357 5
1 [(vii)] (VIII) One representative of the Department of Budget and
2 Management;
3 [(viii)] (IX) One clinical researcher; and
4 [(ix)] (X) One public member at the discretion of the President of
5 the Senate.
6 (4) The Governor shall appoint:
7 (i) One representative of brand name drug corporations;
8 (ii) One representative of generic drug corporations;
9 (iii) One representative of biotechnology companies;
10 (iv) One representative of for–profit health insurance carriers;
11 (v) One representative of employers;
12 (vi) One representative of pharmacy benefits managers;
13 (vii) One representative of pharmacists;
14 (viii) One pharmacologist; [and]
15 (ix) ONE REPRESENTATIVE OF A PATIENT ADVOCACY
16 ORGANIZATION; AND
17 (X) One public member at the discretion of the Governor.
18 (5) Collectively, the members of the Stakeholder Council shall have
19 knowledge of the following:
20 (i) The pharmaceutical business model;
21 (ii) Supply chain business models;
22 (iii) The practice of medicine or clinical training;
23 (iv) Consumer or patient perspectives;
24 (v) Health care costs trends and drivers;
25 (vi) Clinical and health services research; or

6 SENATE BILL 357
1 (vii) The State’s health care marketplace.
2 (6) To the extent practicable and consistent with federal and State law, the
3 membership of the Stakeholder Council shall reflect the racial, ethnic, and gender diversity
4 of the State.
5 (7) From among the membership of the Stakeholder Council, the Board
6 chair shall appoint two members to be cochairs of the Stakeholder Council.
7 (d) (1) The term of a member is 3 years.
8 (2) The initial members of the Stakeholder Council shall serve staggered
9 terms as required by the terms provided for members on October 1, 2019.
10 (e) A member of the Stakeholder Council:
11 (1) May not receive compensation as a member of the Stakeholder Council;
12 but
13 (2) Is entitled to reimbursement for expenses under the Standard State
14 Travel Regulations, as provided in the State budget.
15 21–2C–09.
16 (c) On or before December 31, 2020, and each December 31 thereafter, the Board
17 shall submit to the Senate Finance Committee and the House Health and Government
18 Operations Committee, in accordance with § 2–1257 of the State Government Article, a
19 report that includes:
20 (1) Price trends for prescription drug products;
21 (2) The number of prescription drug products that were subject to Board
22 review and the results of the review; and
23 (3) Any recommendations the Board may have on further legislation
24 needed to make prescription drug products more affordable in the State.
25 (D) IF THE BOARD SETS A NEW UPPER PAYMENT LIMIT, TO THE EXTENT
26 PRACTICABLE, THE BOARD SHALL INCLUDE IN THE FIRST REPORT THAT IS
27 REQUIRED UNDER SUBSECTION (C) OF THIS SECTION AFTER THE UPPER PAYMENT
28 LIMIT HAS BEEN IN EFFECT FOR 1 YEAR INFORMATION ON THE EFFECTS OF THE
29 UPPER PAYMENT LIMIT, BASED ON AVAILABLE TIMELY DATA, FOR THE FOLLOWING:
30 (1) PATIENT OUT–OF–POCKET COSTS INCLUDING WHETHER THE
31 UPPER PAYMENT LIMIT WAS ASSOCIATED WITH INCREASES OR DECREASES IN WHAT
32 PATIENTS PAY FOR PRESCRIPTION DRUG PRODUCTS;

SENATE BILL 357 7
1 (2) PATIENT HEALTH INSURANCE PREMIUMS, INCLUDING WHETHER
2 THE UPPER PAYMENT LIMIT IS ASSOCIATED WITH INCREASES OR DECREASES IN
3 HEALTH INSURANCE COSTS FOR PATIENTS;
4 (3) PHARMACIES OPERATING IN THE STATE, INCLUDING THE IMPACT
5 ON REIMBURSEMENT RATES AND FINANCIAL VIABILITY OF RETAIL AND
6 INDEPENDENT PHARMACIES;
7 (4) PATIENT HEALTH INSURANCE FORMULARIES, INCLUDING
8 WHETHER THE PRESCRIPTION DRUG PRODUCT SUBJECT TO THE UPPER PAYMENT
9 LIMIT REMAINED ON FORMULARIES;
10 (5) PROVIDER–ADMINISTERED MEDICATIONS SUBJECT TO THE
11 UPPER PAYMENT LIMIT, INCLUDING WHETHER PROVIDERS WERE ABLE TO ACQUIRE
12 THE PRESCRIPTION DRUG PRODUCT SUBJECT TO THE UPPER PAYMENT LIMIT AT A
13 RATE TO ACCOUNT FOR ACQUISITION COSTS AND WHETHER THERE WAS AN IMPACT
14 ON PROVIDER REIMBURSEMENT;
15 (6) PATIENT ACCESS TO THE PRESCRIPTION DRUG PRODUCT
16 SUBJECT TO THE UPPER PAYMENT LIMIT, WHICH MAY INCLUDE:
17 (I) WHETHER PRESCRIPTION DRUG PRODUCT SHORTAGES OR
18 OTHER SUPPLY DISRUPTIONS OCCURRED AFTER THE UPPER PAYMENT LIMIT TOOK
19 EFFECT;
20 (II) WHETHER FORMULARY PLACEMENT OR PLAN DESIGN
21 CHANGES MADE THE PRESCRIPTION DRUG PRODUCT SUBJECT TO THE UPPER LIMIT
22 MORE DIFFICULT FOR PATIENTS TO ACCESS, INCLUDING IF INSURANCE PLANS
23 PREFERRED A PRESCRIPTION DRUG PRODUCT WITHOUT AN UPPER PAYMENT LIMIT
24 OVER A PRESCRIPTION DRUG PRODUCT SUBJECT TO AN UPPER PAYMENT LIMIT;
25 (III) WHETHER THE DISTRIBUTION AND DELIVERY OF
26 SPECIALTY OR RARE DISEASE MEDICATIONS FROM OUT–OF–STATE PHARMACIES TO
27 PROVIDERS, PHARMACIES, OR PATIENTS WAS IMPACTED;
28 (IV) WHETHER PATIENTS IN COMMUNITIES OF COLOR,
29 PATIENTS WHO ARE WOMEN, PATIENTS WITH A RARE DISEASE, OR PATIENTS IN
30 RURAL AREAS EXPERIENCED DISPROPORTIONATE ACCESS CHALLENGES; AND
31 (V) WHETHER COST DIFFERENCES AS A RESULT OF THE UPPER
32 PAYMENT LIMIT AFFECTED PATIENTS, PHARMACIES, OR PROVIDERS AND, IF THE
33 COST DIFFERENCE RESULTED IN AN INCREASE IN COSTS, WHO WAS ULTIMATELY
34 RESPONSIBLE FOR BEARING THE INCREASED COST;

8 SENATE BILL 357
1 (7) COVERED ENTITY PROVIDERS PARTICIPATING IN THE 340B DRUG
2 DISCOUNT PROGRAM, INCLUDING THE IMPACT OF THE UPPER PAYMENT LIMIT ON
3 THE OPERATIONS OF THE PROVIDERS AND THEIR CONTRACTED PHARMACIES; AND
4 (8) THE BIOTECHNOLOGY INDUSTRY IN THE STATE, INCLUDING THE
5 IMPACT ON PHARMACEUTICAL RESEARCH AND DEVELOPMENT, INVESTMENT, AND
6 JOB GROWTH.
7 (E) (1) THE BOARD MAY REQUEST INFORMATION NECESSARY TO
8 COMPLETE THE REPORT REQUIRED UNDER SUBSECTIONS (C) AND (D) OF THIS
9 SECTION FROM AN AFFECTED ENTITY.
10 (2) THE ENTITY FROM WHICH INFORMATION WAS REQUESTED UNDER
11 PARAGRAPH (1) OF THIS SUBSECTION SHALL MAKE A GOOD FAITH EFFORT TO
12 PROVIDE THE REQUESTED INFORMATION.
13 21–2C–11.
14 (a) In this section, “Fund” means the Prescription Drug Affordability Fund.
15 [(d) (1) The Board shall be established using special or general funds, which
16 shall be repaid to the State with the funds from the Fund.
17 (2) If the Board receives funding from the Maryland Health Care
18 Commission under paragraph (1) of this subsection, the Board shall repay the funds to the
19 Commission from the Fund over a 3–year period beginning June 1, 2021.]
20 21–2C–13.
21 (a) If, under § 21–2C–07 of this subtitle, the Board finds that it is in the best
22 interest of the State to establish a process for setting upper payment limits for prescription
23 drug products that it determines have led or will lead to an affordability challenge, the
24 Board, in conjunction with the Stakeholder Council, shall draft a plan of action for
25 implementing the process [that includes the criteria the Board shall use to set upper
26 payment limits] IN ACCORDANCE WITH THE REQUIREMENTS OF THIS SECTION.
27 (b) The criteria for setting upper payment limits shall include consideration of:
28 (1) The cost of administering the prescription drug product;
29 (2) The cost of delivering the prescription drug product to consumers; [and]
30 (3) THE EFFECT THE UPPER PAYMENT LIMIT WILL HAVE ON
31 PROVIDERS OF 340B DRUGS;

SENATE BILL 357 9
1 (4) FOR AN UPPER PAYMENT LIMIT ON A DRUG THAT IS DESIGNATED
2 AS A DRUG FOR A RARE DISEASE OR CONDITION, THE IMPACT OF THE UPPER
3 PAYMENT LIMIT ON PATIENTS WITH RARE DISEASES; AND
4 [(3)] (4) (5) Other relevant administrative costs related to the prescription
5 drug product.
6 [(c) The process for setting upper payment limits shall:
7 (1) Prohibit the application of an upper payment limit for a prescription
8 drug product that is on the federal Food and Drug Administration prescription drug
9 shortage list; and
10 (2) Require the Board to:
11 (i) Monitor the availability of any prescription drug product for
12 which it sets an upper payment limit; and
13 (ii) If there becomes a shortage of the prescription drug product in
14 the State, reconsider or suspend the upper payment limit.]
15 (C) (1) IF THE BOARD PREVIOUSLY SET AN UPPER PAYMENT LIMIT FOR A
16 DRUG THAT BECOMES A CURRENT SHORTAGE, THE BOARD MAY RECONSIDER THE
17 PREVIOUSLY SET UPPER PAYMENT LIMIT.
18 (2) THE BOARD MAY NOT:
19 (I) ESTABLISH APPLY A NEW UPPER PAYMENT LIMIT FOR TO A
20 DRUG IN A CURRENT SHORTAGE;
21 (II) ENFORCE AN UPPER PAYMENT LIMIT AGAINST PROVIDER
22 OR PHARMACY REIMBURSEMENT REQUIREMENTS FOR MEDICARE PART C OR PART
23 D PLANS; OR
24 (III) COUNT A PHARMACY DISPENSING FEE TOWARD OR
25 SUBJECT A PHARMACY DISPENSING FEE TO AN UPPER PAYMENT LIMIT.
26 (d) (1) If a plan of action is drafted under subsection (a) of this section, the
27 Board shall submit the plan of action to the Legislative Policy Committee of the General
28 Assembly, in accordance with § 2–1257 of the State Government Article, for its approval.
29 (2) The Legislative Policy Committee shall have 45 days to approve the
30 plan of action.

10 SENATE BILL 357
1 (3) If the Legislative Policy Committee does not approve the plan of action,
2 the Board shall submit the plan to the Governor and the Attorney General for approval.
3 (4) The Governor and the Attorney General shall have 45 days to approve
4 the plan of action.
5 (5) The Board may not set upper payment limits unless the plan is
6 approved, in accordance with this subsection, by:
7 (i) The Legislative Policy Committee; or
8 (ii) 1. The Governor; and
9 2. The Attorney General.
10 21–2C–14.
11 [(a) If a plan of action is approved under § 21–2C–13(d) of this subtitle] IN
12 ACCORDANCE WITH THE PLAN OF ACTION APPROVED BY THE LEGISLATIVE POLICY
13 COMMITTEE ON OCTOBER 22, 2024, the Board may set upper payment limits THROUGH
14 REGULATIONS for prescription drug products that are:
15 (1) Purchased or paid for by a unit of State or local government or an
16 organization on behalf of a unit of State or local government, including:
17 (i) State or county correctional facilities;
18 (ii) State hospitals; and
19 (iii) Health clinics at State institutions of higher education;
20 (2) Paid for through a health benefit plan on behalf of a unit of State or
21 local government, including a county, bicounty, or municipal employee health benefit plan;
22 or
23 (3) Purchased for or paid for by the Maryland State Medical Assistance
24 Program.
25 [(b) The upper payment limits set under subsection (a) of this section shall:
26 (1) Be for prescription drug products that have led or will lead to an
27 affordability challenge; and
28 (2) Be set in accordance with the criteria established in regulations
29 adopted by the Board.

SENATE BILL 357 11
1 (c) (1) The Board shall:
2 (i) Monitor the availability of any prescription drug product for
3 which it sets an upper payment limit; and
4 (ii) If there becomes a shortage of the prescription drug product in
5 the State, reconsider whether the upper payment limit should be suspended or altered.
6 (2) An upper payment limit set under subsection (a) of this section may not
7 be applied to a prescription drug product while the prescription drug product is on the
8 federal Food and Drug Administration prescription drug shortage list.]
9 [21–2C–16.
10 On or before December 1, 2026, the Board, in consultation with the Stakeholder
11 Council, shall report to the Senate Finance Committee and the House Health and
12 Government Operations Committee, in accordance with § 2–1257 of the State Government
13 Article, on:
14 (1) The legality, obstacles, and benefits of setting upper payment limits on
15 all purchases and payor reimbursements of prescription drug products in the State; and
16 (2) Recommendations regarding whether the General Assembly should
17 pass legislation to expand the authority of the Board to set upper payment limits to all
18 purchases and payor reimbursements of prescription drug products in the State.]
19 21–2C–16.
20 (A) (1) THE BOARD, IN CONSULTATION WITH THE STAKEHOLDER
21 COUNCIL, SHALL DETERMINE WHETHER, IN ADDITION TO SETTING UPPER PAYMENT
22 LIMITS IN ACCORDANCE WITH § 21–2C–14 OF THIS SUBTITLE, IT IS IN THE BEST
23 INTEREST OF THE STATE FOR THE BOARD TO ESTABLISH A PROCESS FOR SETTING
24 UPPER PAYMENT LIMITS FOR ALL PURCHASES AND PAYOR REIMBURSEMENTS OF
25 PRESCRIPTION DRUG PRODUCTS IN THE STATE THAT THE BOARD DETERMINES
26 HAVE LED OR WILL LEAD TO AN AFFORDABILITY CHALLENGE.
27 (2) WHEN MAKING A DETERMINATION UNDER PARAGRAPH (1) OF
28 THIS SUBSECTION, THE BOARD SHALL CONSIDER, IF APPLICABLE:
29 (I) CONTRACT AND BUDGET DATA PROVIDED TO THE BOARD
30 THAT DEMONSTRATES SAVINGS TO THE STATE OR LOCAL GOVERNMENTS AS A
31 RESULT OF UPPER PAYMENT LIMITS SET IN ACCORDANCE WITH § 21–2C–14 OF THIS
32 SUBTITLE;

12 SENATE BILL 357
1 (II) SUCCESS OF SETTING UPPER PAYMENT LIMITS IN OTHER
2 STATES; AND
3 (III) EXPECTED SAVINGS FROM MEDICARE MAXIMUM FAIR
4 PRICES SET BY THE CENTERS FOR MEDICARE AND MEDICAID SERVICES.
5 (B) (1) IF THE BOARD MAKES AN AFFIRMATIVE DETERMINATION UNDER
6 SUBSECTION (A) OF THIS SECTION, THE BOARD, IN CONSULTATION WITH THE
7 STAKEHOLDER COUNCIL, SHALL ESTABLISH A PROCESS FOR SETTING UPPER
8 PAYMENT LIMITS FOR ALL PURCHASES AND PAYOR REIMBURSEMENTS OF
9 PRESCRIPTION DRUG PRODUCTS IN THE STATE THAT THE BOARD DETERMINES
10 HAVE LED OR WILL LEAD TO AN AFFORDABILITY CHALLENGE.
11 (2) THE PROCESS ESTABLISHED UNDER PARAGRAPH (1) OF THIS
12 SUBSECTION SHALL:
13 (I) TO THE EXTENT APPROPRIATE, USE THE PLAN OF ACTION
14 APPROVED UNDER § 21–2C–13(D) OF THIS SUBTITLE; AND
15 (II) OTHERWISE COMPLY WITH THE REQUIREMENTS FOR
16 SETTING UPPER PAYMENT LIMITS ESTABLISHED UNDER THIS SUBTITLE.
17 (3) BEFORE ESTABLISHING AN UPPER PAYMENT LIMIT THAT APPLIES
18 TO THE MARYLAND MEDICAL ASSISTANCE PROGRAM, THE BOARD SHALL CONFER
19 WITH THE MARYLAND MEDICAL ASSISTANCE PROGRAM TO APPROVE THE
20 APPLICATION OF THE UPPER PAYMENT LIMIT BY ASSESSING WHETHER THE
21 PROPOSED UPPER PAYMENT LIMIT WILL:
22 (I) CONFLICT WITH THE MEDICAID DRUG REBATES
23 PROGRAM, THE COVERED OUTPATIENT DRUG RULE (CMS–2345–FC), OR ANY
24 OTHER FEDERAL REQUIREMENTS AS APPLICABLE; AND
25 (II) REQUIRE ADDITIONAL FUNDING TO BE ALLOCATED TO THE
26 MARYLAND MEDICAL ASSISTANCE PROGRAM BUDGET.
27 SECTION 2. AND BE IT FURTHER ENACTED, That the Laws of Maryland read
28 as follows:
29 Article – Health – General
30 21–2C–16.
31 (C) (1) IF SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION, IF THE
32 BOARD ESTABLISHES A PROCESS UNDER SUBSECTION (B) OF THIS SECTION, THE

SENATE BILL 357 13
1 BOARD SHALL SET UPPER PAYMENT LIMITS FOR ALL PURCHASES AND PAYOR
2 REIMBURSEMENTS OF PRESCRIPTION DRUG PRODUCTS IN THE STATE IN
3 ACCORDANCE WITH THE PROCESS.
4 (2) THIS SUBSECTION DOES NOT APPLY WITH RESPECT TO:
5 (I) PAYOR REIMBURSEMENTS UNDER MEDICARE PART C AND
6 D PLANS;
7 (II) PURCHASES UNDER THE FEDERAL 340B DRUG PRICING
8 PROGRAM; AND
9 (III) PURCHASES AND PAYOR REIMBURSEMENTS UNDER BY
10 FEDERAL AGENCIES OR FEDERAL PROGRAMS THAT ARE THE STATE IS PREEMPTED
11 FROM REGULATING BY FEDERAL LAW INCLUDING:
12 1. THE DEPARTMENT OF DEFENSE;
13 2. THE DEPARTMENT OF VETERANS AFFAIRS;
14 3. THE PUBLIC HEALTH SERVICE;
15 4. THE UNITED STATES COAST GUARD;
16 5. TRICARE;
17 6. THE FEDERAL EMPLOYEES HEALTH BENEFIT PLAN;
18 AND
19 7. ANY OTHER EXCLUSIVE FEDERAL PROGRAM AS
20 APPLICABLE.
21 SECTION 3. AND BE IT FURTHER ENACTED, That:
22 (a) Section 2 of this Act is contingent on the Prescription Drug Affordability Board
23 setting upper payment limits on two prescription drugs in accordance with § 21–2C–14 of
24 the Health – General Article, as enacted by Section 1 of this Act, and each upper payment
25 limit being in effect for 1 year.
26 (b) Within 5 days after the conditions described in subsection (a) of this section
27 are met, the Prescription Drug Affordability Board shall notify the Department of
28 Legislative Services.
29 (c) If notice is received by the Department of Legislative Services in accordance
30 with subsection (b) of this section on or before September 31 September 30, 2030, Section 2

14 SENATE BILL 357
1 of this Act shall take effect on the date the notice is received by the Department of
2 Legislative Services.
3 (d) If notice is not received by the Department of Legislative Services on or before
4 December 31 September 30, 2030, Section 2 of this Act, with no further action required by
5 the General Assembly, shall be null and void.
6 SECTION 4. AND BE IT FURTHER ENACTED, That, subject to Section 3 of this
7 Act, this Act shall take effect October 1, 2025.
Approved:
________________________________________________________________________________
Governor.
________________________________________________________________________________
President of the Senate.
________________________________________________________________________________
Speaker of the House of Delegates.

[DELETED: :CA      ( w t G S a p t t G f h a t d o _ a _ o _ A P a ( F t p o a t m o t P D A S C r t P D A B u c p t t s B b t r]
[DELETED:  S  B  A S  A  ( B  A S  A  ( B  A  S  A  ( B  A S  A  ( B  A S  A  (  S T A 2  ( I  ( “ b  ( “ a  ( “]
[DELETED: S 3  ( ( “ a   ( “ b ) “C”:UE    LF A C O T F O A R’DSD;NS R H AE    O D B T O T B I S T.  () “](   ( A a   ( A   ( A m  () “](   ( ( E    ( E d   ( S p  () “]( a  () “ C m t P D A]( S 2  ( T]
[DELETED:  S   ( T a  ( ( T S C c o 26 m a i a   ( T    ( O    ( O    ( O    ( O r o a s a o f s    ( O r o a s o f d c    ( O    ( ;    () h s r s i p d    () () O H   ( T    ( O    ( O    ( O    ( O    ( O    (      O]
[DELETED: S 5    ()  r o t D o B a](V M    ()  O](    () O]( t   ( T    ( O    ( O    ( O    ( O    ( O    ( O    ( O    ( O ad    ( R O A P AN       O   ( C t m o t S C s h k    ( T    ( S    ( T    ( C    ( H    ( C]
[DELETED:  S     ( T   ( T m o   ( F c  ( ( T   ( T t  ( A   ( M b   ( I T 2  ( O s O r   ( P   ( T r   ( A r t B m h o f l n   )IBF O N  O S I I T F R T I C   T A ,    )P– OTOFP C I W T ]
[DELETED: S 7   )PS  U P L I A W I O D I    )PS TE  R R A F V O R A    )P H I FS I    )PRA M S T TT     ) A T T P D PT      )H     )IH F P O P D D F P T AS I I I P     )IH T D A D OTOFSS S ,     )WVH P I C O CR W A WN P W A R DE O P IS      )HS S D ,S  ]
[DELETED:  S    )C3  M S     )TS TE T T     )()TH O M R I N T T R R U S C A D O T)(    )  O T S S M A G F E TN  2  ( I  ( ( T s   ( I t B r f f t M H C C C. 2  ( I i d B i c w t S C s d a p o a f i t pst i t c t B s u t s u ps.  ( T   ( T   ( T;ad    E T U P L W H O  B;]
[DELETED: S 9    A D F A R D O CN T I O T US     () O]()( d  ( T   ( P d p t i o t f F a D A p d s   ( R    ( M t a o a p d p f w    ( I t. ) ( IF OE  O   TB: O    ) S AYT  E   ) IN E A   APC;S    ) IO A P D F T O  ( ( I B A   ( T p]
[DELETED:  S    ( I t   ( T t   ( T B m n s u p l u t p i a    ( T    ( 1 T     2 T 2  ( I a p o a i a u § 2 o t se] E OO2,2 C  ,     ( P o p f b a u o S o l g o a o    ( S    ( S    ( H   ( P l o   ( P P  ( T   ( B f p d p t h l o w l t a a   ( B s i a w t c e i r a]
[DELETED: S 1  ( ( T    ( M t a o a p d p f w    ( I t   ( A b f. 2  O C s r t t S F C a t H H a G A   ( T a   ( R r w t G A s p p. ) ( TB,H OD I C W T T,L R    E 24 T O D P I T T T T O D   W( M A D U P  ON  OR B,:   ) CO O D S T T T O L G A A   2]
[DELETED:  S    ) IUS    ) EMMIX S F E A ACMMS. E E E E ) ( IF O A O T SN T OD I C W T),B C OL S E A P F S U L F A P A P R O D P I T T T T O D    T( P E U P  O T   ) TOE   D E 2();   ) IT C W T R F    A E S RM  OMAP, T A E S R T A TMA O T U P L B A W T    ) CMDO W T E R E,CODR(M T O U R U  O AE     ) IEMAP E S RT   S a A 2 ) ( IS()F U T P  O T SN I T() B N ]
[DELETED: S 1 S S U P L F A P A P O P D P I T T IS   T:   ) PMPA E A  PL    ) P3BDIU U T F  R RM      ) IU A P R URT T    EP   WI      TDD E E      TDVA E E F      TPHS U E E      TUSCG N T O U      T     TFEHBP E M E E LN       O E F P A    S  ( S s t l  ( W a m t P D A B s n t D o L  ( I w]
[DELETED:  S  o t A s t e o t d t n i r b t D o L  ( I D t  S A          G               ]